bioAffinity Technologies announced its CyPath Lung test will be featured at the invitation-only Cleveland Clinic symposium on early lung cancer detection on April 16, 2026, with CMO Gordon Downie participating in a panel.
Key takeaways
CyPath Lung test to be featured at Cleveland Clinic's seventh annual 'Advances in Early Lung Cancer Detection' symposium on April 16, 2026.
Gordon Downie, MD, PhD, Chief Medical Officer, will discuss lung nodule management and CyPath Lung benefits on a panel.
Symposium is invitation-only, gathering global leaders in lung cancer detection and new technologies.
This marks bioAffinity's seventh invitation to present at the symposium.
CyPath Lung uses flow cytometry and AI, showing 92% sensitivity, 87% specificity, 88% accuracy in clinical data for high-risk patients with small nodules.